Anti-hepatitis B Virus Treatment with Tenofovir Amibufenamide Has No Impact on Blood Lipids: A Real-world, Prospective, 48-week Follow-up Study  

作　　者：Yue Chen Wenkang Gao Huikuan Chu Afnan Ahmed Mohamed Al-Asbahi Shengqi Yan Hang Yuan Jiake Che Zilu Cheng Zexuan Li Jin Ye Rong Lin Xiaohua Hou Fan Du Ling Yang 

机构地区：[1]Division of Gastroenterology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第12期997-1008,共12页临床与转化肝病杂志(英文版)

基　　金：funded by the National Natural Science Foundation of China[82270614,81974078,81570530,and 81370550 to LY,82000561to HC];the National Key R&D Program of China[2023YFC2413804 to LY and 2022YFA1305600 to HC];the Science Foundation of Hubei Province[2019ACA133 to LY]and the Science Foundation of Union Hospital[2021xhyn005]to HC.

摘　　要：Background and Aims:The effect of tenofovir amibufenamide(TMF)on blood lipid profiles in patients with chronic hepatitis B(CHB)remains unclear.This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.Methods:A total of 91 patients with CHB undergoing TMF treatment for 48 weeks were divided into two groups:Lipid Normal(n=42)and Lipid Abnormal(n=49),based on baseline blood lipid levels.Lipid indices,virological responses,and biochemical indicators were compared between the two groups.Clinical observations were further verified through in vitro experiments.Results:After an average follow-up of 373±121 days,lipid indices in all 91 patients had not significantly changed compared with baseline(total cholesterol:4.67 vs.4.69 mmol/L,P=0.2499;triglycerides:1.08 vs.1.04 mmol/L,P=0.4457;high-density lipoprotein cholesterol:1.25 vs.1.25 mmol/L,P=0.3063;low-density lipoprotein cholesterol:3.03 vs.3.02 mmol/L,P=0.5765).Subgroup comparisons showed lipid indices remained stable.Among treatment-naïve patients(n=82),complete viral suppression rates were 23.2%,59.8%,70.7%,and 86.6%at four,12,24,and 48 weeks,respectively.Cellular experiments revealed that TMF did not promote lipid metabolism in primary hepatocytes and AML12 cells.Conclusions:Regardless of baseline blood lipid characteristics,48 weeks of antiviral treatment with TMF in patients with CHB had no significant lipid-raising effect.

关 键 词：Tenofovir amibufenamide Antiviral treatment Chronic hepatitis B Blood lipid Virological response Palmitic acid 

分 类 号：R51[医药卫生—内科学]